Evidence map›Paper›PMID 37415925›Full record

ArticleInternational journal of cardiology. Cardiovascular risk and prevention2023

Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events.

So Ikebe, Masanobu Ishii, Yasuhiro Otsuka, Taishi Nakamura, Kenichi Tsujita, Tetsuya Matoba, Takahide Kohro, Yusuke Oba, Tomoyuki Kabutoya, Yasushi Imai and 12 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in International journal of cardiology. Cardiovascular risk and prevention, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 1 country.

So IkebeDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Masanobu IshiiDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yasuhiro OtsukaDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Taishi NakamuraDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Kenichi TsujitaDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Tetsuya MatobaDepartment of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Takahide KohroDepartment of Clinical Informatics, Jichi Medical University School of Medicine, Tochigi, Japan.
Yusuke ObaDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Tomoyuki KabutoyaDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Yasushi ImaiDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan.
Kazuomi KarioDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Arihiro KiyosueDepartment of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Yoshiko MizunoDepartment of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Kotaro NochiokaDivision of Cardiovascular Medicine, Tohoku University Hospital, Sendai, Japan.
Masaharu NakayamaDepartment of Medical Informatics, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Takamasa IwaiDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Yoshihiro MiyamotoOpen Innovation Center, National Cerebral and Cardiovascular Center, Osaka, Japan.
Hisahiko SatoPrecision Inc., Tokyo, Japan.
Naoyuki AkashiDivision of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Hideo FujitaDivision of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Ryozo NagaiJichi Medical University School of Medicine, Tochigi, Japan.
CLIDAS research group
Jichi Medical University · JPKumamoto University · JPNational Cerebral and Cardiovascular Center · JPDevelopment Bank of Japan · JPKyushu University · JPTohoku University · JPTohoku University Hospital · JPUniversity of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Heart failure (HF) is associated with a high bleeding risk after percutaneous coronary intervention (PCI). Additionally, major bleeding events increase the risk of subsequent major adverse cardiac events (MACE). However, whether brain natriuretic peptide (BNP) levels and major bleeding events following PCI are associated with MACE and all-cause death remains unknown. This study aimed to investigate the impact of HF severity or bleeding on subsequent MACE and all-cause death. Methods: The Clinical Deep Data Accumulation System (CLIDAS), a multicenter database involving seven hospitals in Japan, was developed to collect data from electronic medical records. This retrospective analysis included 7160 patients who underwent PCI between April 2014 and March 2020 and completed a three-year follow-up. Patients were divided according to the presence of HF with high BNP (HFhBNP) (>100 pg/ml) and major bleeding events within 30 days post-PCI (30-day bleeding): HFhBNP with bleeding (n = 14), HFhBNP without bleeding (n = 370), non-HFhBNP with bleeding (n = 74), and non-HFhBNP without bleeding (n = 6702). Results: In patients without 30-day bleeding, HFhBNP was a risk factor for MACE (hazard ratio, 2.19; 95% confidence interval, 1.56-3.07) and all-cause death (hazard ratio, 1.60; 95% confidence interval, 1.60-2.23). Among HFhBNP patients, MACE incidence was higher in patients with 30-day bleeding than in those without bleeding, but the difference was not significant (p = 0.075). The incidence of all-cause death was higher in patients with bleeding (p = 0.001). Conclusions: HF with high BNP and bleeding events in the early stage after PCI might be associated with subsequent MACE and all-cause death.

Indexed as

Acute coronary syndromeBleedingHeart failureHigh BNPMajor adverse cardiac eventPercutaneous coronary intervention

Identifiers

PMID37415925
PMCPMC10320317
OpenAlexW4381988212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.